SK Biopharmaceuticals Announces 100,000 Patients Globally Have Been Treated with Cenobamate Through Sales of XCOPRI® and ONTOZRY® in the U.S., Europe, Israel, and Canada

Milestone Coincides with SK Biopharmaceuticals’ Global Plan Expanding Cenobamate Access to More Than 100 Markets Worldwide GYEONGGI, Korea, and ROME, March 11, 2024 /PRNewswire/ — SK Biopharmaceuticals Co., Ltd., a global biotech focused on developing treatments for central nervous…